These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

310 related articles for article (PubMed ID: 33268125)

  • 1. Residual tumor characteristics of esophageal squamous cell carcinoma after neoadjuvant chemoradiotherapy.
    Tang H; Jiang D; Zhang S; Zeng Z; Tan L; Hou Y; Wang Q; ; Wang H; Zhu J; Shen Y; Yin J; Ge D
    J Thorac Cardiovasc Surg; 2021 Dec; 162(6):1632-1641. PubMed ID: 33268125
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Residual esophageal cancer after neoadjuvant chemoradiotherapy frequently involves the mucosa and submucosa.
    Shapiro J; ten Kate FJ; van Hagen P; Biermann K; Wijnhoven BP; van Lanschot JJ
    Ann Surg; 2013 Nov; 258(5):678-88; discussion 688-9. PubMed ID: 24096766
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Residual tumor model in esophageal squamous cell carcinoma after neoadjuvant immunochemotherapy: Frequently involves the mucosa and/or submucosa.
    Gao L; Hong ZN; Wu L; Yang Y; Kang M
    Front Immunol; 2022; 13():1008681. PubMed ID: 36569913
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Oncologic Outcome of Patients With Pathologic T0 Esophageal Squamous Cell Carcinoma After Neoadjuvant Chemoradiotherapy.
    Chen SB; Wang X; Chen YP
    Cancer Control; 2024; 31():10732748241284905. PubMed ID: 39259832
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Pathologic responses and surgical outcomes after neoadjuvant immunochemotherapy versus neoadjuvant chemoradiotherapy in patients with locally advanced esophageal squamous cell carcinoma.
    Xu L; Wei XF; Li CJ; Yang ZY; Yu YK; Li HM; Xie HN; Yang YF; Jing WW; Wang Z; Kang XZ; Zhang RX; Qin JJ; Xue LY; Bi N; Chen XK; Li Y
    Front Immunol; 2022; 13():1052542. PubMed ID: 36466925
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Survival Impact of Total Resected Lymph Nodes in Esophageal Cancer Patients With and Without Neoadjuvant Chemoradiation.
    Ho HJ; Chen HS; Hung WH; Hsu PK; Wu SC; Chen HC; Wang BY
    Ann Surg Oncol; 2018 Dec; 25(13):3820-3832. PubMed ID: 30284131
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Residual carcinoma cells after chemoradiotherapy for esophageal squamous cell carcinoma patients: striving toward appropriate judgment of biopsy.
    Fujishima F; Taniyama Y; Nakamura Y; Okamoto H; Ozawa Y; Ito K; Ishida H; Konno-Kumagai T; Kasajima A; Taniuchi S; Watanabe M; Kamei T; Sasano H
    Dis Esophagus; 2018 Jul; 31(7):. PubMed ID: 29346536
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Immune cell patterns before and after neoadjuvant immune checkpoint blockade combined with chemoradiotherapy in locally advanced esophageal squamous cell carcinoma.
    Zheng DD; Li YY; Yuan XY; Lu JL; Zhang MF; Fu J; Zhang CZ
    BMC Cancer; 2024 May; 24(1):649. PubMed ID: 38802821
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Accuracy of detecting residual disease after neoadjuvant chemoradiotherapy for esophageal squamous cell carcinoma (preSINO trial): a prospective multicenter diagnostic cohort study.
    Zhang X; Eyck BM; Yang Y; Liu J; Chao YK; Hou MM; Hung TM; Pang Q; Yu ZT; Jiang H; Law S; Wong I; Lam KO; van der Wilk BJ; van der Gaast A; Spaander MCW; Valkema R; Lagarde SM; Wijnhoven BPL; van Lanschot JJB; Li Z
    BMC Cancer; 2020 Mar; 20(1):194. PubMed ID: 32143580
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Identification of Optimal Parameters for Assessing Lymph Node Status of Patients with Esophageal Squamous Cell Carcinoma After Neoadjuvant Chemoradiotherapy.
    Huang X; Jiang D; Jian Z; Zeng Z; Zhang S; Fan H; Sun T; Tang H; Hou Y; Tan L
    Ann Surg Oncol; 2024 Feb; 31(2):883-891. PubMed ID: 38038788
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Adjuvant chemoradiotherapy plus pembrolizumab for locally advanced esophageal squamous cell carcinoma with high risk of recurrence following neoadjuvant chemoradiotherapy: a single-arm phase II study.
    Guo JC; Huang TC; Kuo HY; Lin CC; Hsu FM; Cheng JC; Huang YL; Hsieh MS; Huang PM; Lee JM; Wu SL; Hsu CH
    Cancer Immunol Immunother; 2024 Sep; 73(11):230. PubMed ID: 39249605
    [TBL] [Abstract][Full Text] [Related]  

  • 12. A Pathological Study of Residual Cancer in the Esophageal Wall Following Neoadjuvant Chemoradiotherapy: Focus on Esophageal Squamous Cell Carcinoma Patients with False Negative Preoperative Endoscopic Biopsies.
    Chao YK; Tsai CY; Chang HK; Tseng CK; Liu YH; Yeh CJ
    Ann Surg Oncol; 2015 Oct; 22(11):3647-52. PubMed ID: 25672562
    [TBL] [Abstract][Full Text] [Related]  

  • 13. [The value of the planned neoadjuvant radiotherapy or chemoradiotherapy for the non-radical resection of esophageal squamous cell carcinoma].
    Ni WJ; Deng W; Xiao ZF; Zhou ZM; Wang X; Chen DF; Feng QF; Liang J; Lyu JM; Bi N; Deng L; Zhang T; Wang WQ; Xue Q; Gao SG; Mu JW; Mao YS; Wang DL; Zhao J; Gao YS; Huang JF; Tan FW; Zhao L; Lyu F; Zhang GC
    Zhonghua Zhong Liu Za Zhi; 2019 Apr; 41(4):295-302. PubMed ID: 31014056
    [No Abstract]   [Full Text] [Related]  

  • 14. Histomorphologic tumor regression and lymph node metastases determine prognosis following neoadjuvant radiochemotherapy for esophageal cancer: implications for response classification.
    Schneider PM; Baldus SE; Metzger R; Kocher M; Bongartz R; Bollschweiler E; Schaefer H; Thiele J; Dienes HP; Mueller RP; Hoelscher AH
    Ann Surg; 2005 Nov; 242(5):684-92. PubMed ID: 16244542
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Development and Validation of a Recurrence-Free Survival Prediction Model for Locally Advanced Esophageal Squamous Cell Carcinoma with Neoadjuvant Chemoradiotherapy.
    Zhou Y; He W; Guo P; Zhou C; Luo M; Liu Y; Yang H; Qin S; Leng X; Huang Z; Liu Y
    Ann Surg Oncol; 2024 Jan; 31(1):178-191. PubMed ID: 37751117
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Prognostic significance of positive lymph node regression grade to neoadjuvant chemoradiation for esophageal squamous cell carcinoma.
    Yehan Z; Ying L; Peng G; Zongyao H; Chengmin Z; Hong Y; Sheng Q; Jie Z; Yi W; Xuefeng L; Wenwu H; Qifeng W; Yang L
    J Surg Oncol; 2024 Mar; 129(4):708-717. PubMed ID: 38124398
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Oncologic Outcomes According to Remnant Lymph Node Metastases in Pathologic T0 (ypT0) Esophageal Squamous Cell Carcinoma Following Prospective Neoadjuvant Therapy and Surgery.
    Cho HJ; Kim YH; Kim HR; Kim DK; Park SI; Kim JH; Kim SB
    Ann Surg Oncol; 2015; 22(6):1851-7. PubMed ID: 25344308
    [TBL] [Abstract][Full Text] [Related]  

  • 18. A phase-II/III randomized controlled trial of adjuvant radiotherapy or concurrent chemoradiotherapy after surgery versus surgery alone in patients with stage-IIB/III esophageal squamous cell carcinoma.
    Ni W; Yu S; Zhang W; Xiao Z; Zhou Z; Chen D; Feng Q; Liang J; Lv J; Gao S; Mao Y; Xue Q; Sun K; Liu X; Fang D; Li J; Wang D
    BMC Cancer; 2020 Feb; 20(1):130. PubMed ID: 32070309
    [TBL] [Abstract][Full Text] [Related]  

  • 19. The patterns and risk factors for relapse in oesophageal squamous cell cancers that achieve pathological complete response to neoadjuvant chemoradiotherapy.
    Zhong J; Fang S; Chen R; Yuan J; Xie X; Lin T; Liu M; Liu Q; Fu J
    Eur J Cardiothorac Surg; 2024 Jun; 65(6):. PubMed ID: 38810125
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Clinical tools do not predict pathological complete response in patients with esophageal squamous cell cancer treated with definitive chemoradiotherapy.
    Molena D; Sun HH; Badr AS; Mungo B; Sarkaria IS; Adusumilli PS; Bains MS; Rusch VW; Ilson DH; Rizk NP
    Dis Esophagus; 2014; 27(4):355-9. PubMed ID: 24033404
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 16.